Physician profile
Lamson Benjamin DO
NPI 1831913425
$1,400.45
in general payments reported to CMS, 2019-2025
19 companies · $1,345 in 2025
The $1,345 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $55.07 · 2025: $1,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,228.95 |
| Education | $171.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $232.32 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $227.55 | 2025 | Austedo Xr |
| Ucb, INC. | $193.09 | 2025 | Zilbrysq, Fintepla, Briviact |
| Zoll Respicardia, INC. | $89.77 | 2025 | Remede System |
| Pfizer INC. | $86.07 | 2025 | |
| Axsome Therapeutics, INC. | $83.21 | 2025 | Symbravo |
| Eisai INC. | $69.38 | 2025 | |
| Emd Serono, INC. | $55.68 | 2025 | |
| Lilly USA, LLC | $54.97 | 2025 | Kisunla |
| Takeda Pharmaceuticals U.S.A., INC. | $52.54 | 2025 | Hyqvia |
| Harmony Biosciences LLC | $47.99 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $43.38 | 2024-2025 | Rexulti |
| Sk Life Science, INC. | $33.15 | 2024 | |
| Tanabe Pharma America, INC. | $27.62 | 2025 | Radicava |
| Novartis Pharmaceuticals Corporation | $25.17 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $24.85 | 2025 | Zeposia |
| Janssen Biotech, INC. | $19.52 | 2025 | |
| Ge Healthcare | $19.21 | 2025 | |
| Acadia Pharmaceuticals INC | $14.98 | 2025 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lamson DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.